Physician profile
John M Lyons
NPI 1417156068
$7,666.67
in general payments reported to CMS, 2019-2025
30 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $465 · 2021: $456 · 2022: $991 · 2023: $1,408 · 2024: $1,794 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,039.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,524.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,091.32 | 2020-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $821.83 | 2019-2025 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $406.89 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $393.83 | 2019-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $343.29 | 2022-2025 | |
| Pfizer INC. | $330.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $314.99 | 2022-2025 | Dupixent |
| Celgene Corporation | $160.73 | 2022-2023 | Zeposia |
| Qol Medical, LLC | $154.64 | 2019-2025 | Sucraid, Sucraid |
| Allergan, INC. | $140.02 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $139.07 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $121.05 | 2021-2024 | Linzess |
| Glaxosmithkline, LLC. | $105.64 | 2020-2025 | Benlysta, Trelegy Ellipta |
| Lilly USA, LLC | $101.27 | 2024-2025 | Omvoh, Zepbound |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $89.89 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $58.36 | 2019-2023 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $55.26 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $48.79 | 2019 | |
| Aimmune Therapeutics, INC. | $42.45 | 2024 | |
| Shionogi INC | $38.33 | 2019 | |
| Merck Sharp & Dohme LLC | $35.83 | 2024 | Dificid, Zerbaxa |
| Angiodynamics, INC. | $21.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.77 | 2021 | |
| Alfasigma USA, INC. | $19.41 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.09 | 2021 | |
| Exact Sciences Corporation | $18.74 | 2024 | Cologuard Collection Kit |
| Grifols USA, LLC | $17.96 | 2024 | Xembify |
| Intercept Pharmaceuticals, INC. | $16.01 | 2022 | |
| Pentax of America, INC. | $15.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.